Singapore Overview
Financial Performance
Business Operations & Assets
Business Details
Reason For Sale
Description
Key highlights
• A$8.5 million in verified historical revenue with exceptional customer retention
• ~93% materials contribution margin and recurring monthly consumable model
• Newly lodged foundational patent protecting proprietary formulation technology
• Clear path to automated Australian manufacturing scale-up
Scale potential: Capturing just 1% of the addressable US market could generate around A$500 million in monthly revenue.
Investor return profile: Dual-track opportunity with potential early cash dividends plus primary exit via strategic pharmaceutical acquisition or IPO. Management targets 25x–100x returns on each A$100,000 investment packet.
This is a commercial-stage pharmaceutical company with proven demand, not a pre-revenue science project. Capital will accelerate production capacity and global commercialisation.
Singapore-based and regional investors please email to request the full confidential prospectus.
AI Business Analysis
Get AI-assisted insights into this business’s strengths, risks, key questions, and due diligence points.
Understand this opportunity more quickly
Review the key strengths, financial considerations, risks and due diligence points identified from the listing.
Submit Enquiry
Introduce yourself and explain what you would like to know about this opportunity.
Listing information is provided by the listing provider or their representatives and has not been independently verified by our platform. Users should verify all information and conduct their own due diligence before making any decision, payment or commitment.
All communications, agreements, transactions, disputes and claims are solely between the relevant parties.
Learn how to avoid scams